Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | USP1 | O94782 | 1/20 | 0.49 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118940 | 0.88 | APP (0.59) | APPSLC2A1ACHEPOLBEGFR | |
| SCHEMBL3110732 | 0.86 | APP (0.57) | APPSLC2A1ACHEPOLBEGFR | |
| SCHEMBL3123122 | 0.84 | APP (0.55) | APPSLC2A1ACHEPOLBEGFR | |
| SCHEMBL11561410 | 0.82 | NPC1 (0.65) | ACHESMN1; SMN2ALDH1A1MAPTNPSR1 | |
| SCHEMBL27783096 | 0.82 | NPC1 (0.65) | ACHESMN1; SMN2ALDH1A1MAPTNPSR1 | |
| SCHEMBL4864671 | 0.81 | APP (0.70) | APPSLC2A1ACHEPOLBEGFR | |
| SCHEMBL3110583 | 0.81 | APP (0.70) | APPSLC2A1ACHEPOLBEGFR | |
| SCHEMBL3119160 | 0.81 | APP (0.70) | APPSLC2A1ACHEPOLBEGFR | |
| SCHEMBL3116085 | 0.80 | TUBB4A (0.53) | EGFRTNKSTNKS2TOP2ATOP2B | |
| SCHEMBL4859121 | 0.80 | APP (0.68) | APPSLC2A1ACHEPOLBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | claimed |
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MKI67, CCNI, CCNA1 | APP 3879/4885SLC2A1 337/4885ACHE 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.